Completed NA INTERVENTIONAL 2-arm NCT05947708

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

A Post-Market, Single Blind, Randomized Clinical Prospective Study on Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

Sponsor: Outset Medical

Conditions End Stage Renal Disease on Dialysis

Interventions Dialysate Flow Rate

Updated 3 times since 2023 Last updated: Jul 7, 2023 Started: Sep 15, 2019 Primary completion: Oct 15, 2019 Completion: Jan 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on End Stage Renal Disease on Dialysis, this trial is completed. The trial is conducted by Outset Medical and has accumulated 3 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Aug 2023 — Jul 2024 [monthly]

Completed NA

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Outset Medical
White Plains Hospital

Data source: Outset Medical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Jose, United States